Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 502

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 502
---
 | ​                                      | ​ |   -387 | ​ | ​ | ​ | ​    | ​ | -5,026 | ​ | ​ |
| Cash, beginning of the period                                            | ​ | ​ | ​                                      | ​ |    434 | ​ | ​ | ​ | ​    | ​ |  5,048 | ​ | ​ |
| Cash, end of the period                                                  | ​ | ​ | ​                                      | $ |     47 | ​ | ​ | ​ | ​    | $ |     22 | ​ | ​ |
| Supplemental disclosure of cash flow information:                        | ​ | ​ | ​                                      | ​ |      ​ | ​ | ​ | ​ | ​    | ​ |      ​ | ​ | ​ |
| Cash paid for interest                                                   | ​ | ​ | ​                                      | $ |      — | ​ | ​ | ​ | ​    | $ |      — | ​ | ​ |
| Cash paid for income taxes                                               | ​ | ​ | ​                                      | $ |      — | ​ | ​ | ​ | ​    | $ |      — | ​ | ​ |
| Supplemental disclosure of non-cash financing and investing activities:  | ​ | ​ | ​                                      | ​ |      ​ | ​ | ​ | ​ | ​    | ​ |      ​ | ​ | ​ |
| Deferred transaction costs in accounts payable                           | ​ | ​ | ​                                      | $ |    278 | ​ | ​ | ​ | ​    | $ |      — | ​ | ​ |
| Cancellation of member units related to Metavagen license termination    | ​ | ​ | ​                                      | $ |      — | ​ | ​ | ​ | ​    | $ |    239 | ​ | ​ |
| Issuance of Class A member units in exchange for CD-47 License Agreement | ​ | ​ | ​                                      | $ |      — | ​ | ​ | ​ | ​    | $ |    786 | ​ | ​ |

The accompanying notes are an integral part of these unaudited condensed financial statements. F-56

TABLE OF CONTENTS

#### LIMINATUS PHARMA, LLC

### NOTES TO CONDENSED FINANCIAL STATEMENTS

#### SEPTEMBER 30, 2024
<div align='center'>**(Unaudited)**</div>

### Note 1. Organization and Description of Business Operations
Liminatus Pharma, LLC (“Liminatus” or the “Company”) was